BACE1 and Alzheimer disease: Based on the calculated effective dose of [18F]PF-06684511, the administration of 400 MBq corresponds to a radiation dose of 10 mSv, suggesting that [18F]PF-06684511 can be used in clinical trials to measure the brain BACE1 level and/or the occupancy by BACE1 inhibitors in AD.